# Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

> **NCT01947907** · PHASE2 · COMPLETED · sponsor: **Ascendis Pharma A/S** · enrollment: 53 (actual)

## Conditions studied

- Growth Hormone Deficiency (GHD)

## Interventions

- **DRUG:** ACP-001
- **DRUG:** Human Growth Hormone

## Key facts

- **NCT ID:** NCT01947907
- **Lead sponsor:** Ascendis Pharma A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2015-07
- **Final completion:** 2015-09
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2017-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01947907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01947907, "Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01947907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*